Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis

摘要: BACKGROUND The standard treatment for localised squamous cell carcinoma of the anal canal (SCCAC) is chemoradiotherapy (CRT) with infusional 5-fluorouracil (5-FU) and mitomycin. Because 5-FU capecitabine have offered similar efficacy in many phase-III trials solid tumours, studies tested this setting SCCAC. However, these are small reported variable results. Therefore, a systematic review meta-analysis was performed. METHODS Medline, Scopus Embase were searched that evaluated outcomes used as substitute CRT primary endpoint complete response rate (CRR) at 6 months. Metaprop analysis CRR-based on pooled estimates proportions corresponding 95% confidence intervals (95%CI) calculated base Freeman-Tukey double arcsine transformation. RESULTS We retrieved 300 studies, which six met our eligibility criteria. dose ranged from 500 mg/m2 to 825 BID 5 days per week during radiation. With total 218 patients, median follow-up 21.5 months (14-23). three (N = 132 patients) CRR 88% (83%-94%), considering all clinical stages. overall patients), different intervals, showed an 91% (87%-95%). Rates locoregional relapse varied 3.2% 21%. majority patients completed planned radiotherapy (93.5%-100%) any chemotherapy interruption up 55.8% patients. CONCLUSIONS Capecitabine acceptable more convenient alternative SCCAC, offering those by trials.